Video - Floretina.com
hot-topics-news

Breaking news

Hot topics

The editorial team at Floretina.com is committed to select the news of the month. We will interview established physicians, as well as young ophthalmologists, scientific advisors and Industry representatives. Register on the website to receive news notifications!

Search in Hot Topic section

Home Monitoring, a pathway to personalisation
Date: Jun 07, 2022
Home Monitoring, a pathway to personalisation

A new idea to bridge the gap between patient and physician: among the most recent innovations in ophthalmology, and retina in particular, the development of home monitoring systems shows potential to improve efficacy of treatment and care. Read more

Post hoc analysis of trial data shows rapid DR progression In untreated fellow eyes
Date: Apr 30, 2022
Post hoc analysis of trial data shows rapid DR progression In untreated fellow eyes

Untreated fellow eyes of patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR) are at risk of rapid disease progression and vision loss, according to researchers from the Mayo Clinic of Rochester, Minnesota. Read more

A new biomarker for progression of geographic atrophy can be found in choroidal vascularity index, study shows.
Date: Apr 29, 2022
A new biomarker for progression of geographic atrophy can be found in choroidal vascularity index, study shows.

Choroidal vascularity index (CVI) impairment is strictly related to the progression of geographic atrophy (GA) and could be considered a predictor of disease progression, as well as a new potential biomarker for the evaluation of treatment efficacy, a clinical trial shows. Read more

Positive Phase III topline results of novel eye drop candidate for the treatment of presbyopia paves the way to regulatory submission in the U.S.
Date: Apr 26, 2022
Positive Phase III topline results of novel eye drop candidate for the treatment of presbyopia paves the way to regulatory submission in the U.S.

Following successful Phase 2b results, a novel eye drop candidate for the treatment of presbyopia achieved topline results in the NEAR-1 and NEAR-2 Phase III clinical trials, according to a press release by Orasis Pharmaceuticals. Read more

EC approves Brolucizumab for the treatment of DME
Date: Apr 25, 2022
EC approves Brolucizumab for the treatment of DME

The European Commission has granted approval to Beovu® 6mg (brolucizumab, Novartis) for the treatment of visual impairment related to diabetic macular oedema. Read more

Zeiss receives U.S. FDA clearance for Quatera 700 phaco technology
Date: Apr 24, 2022
Zeiss receives U.S. FDA clearance for Quatera 700 phaco technology

The U.S. Food and Drug Administration has granted clearance to Quatera 700 from Zeiss, a complete and digitally-integrated phacoemulsification system designed to optimise workflow efficiency from the clinic to the operating theatre. Read more

Use of phosphodiesterase type 5 inhibitors may be associated with severe ocular adverse effects
Date: Apr 23, 2022
Use of phosphodiesterase type 5 inhibitors may be associated with severe ocular adverse effects

Regular use of phosphodiesterase type 5 inhibitors (PDE5Is) was associated with an increased risk for serous retinal detachment (SRD), ischemic optic neuropathy (ION) and retinal vascular occlusion (RVO) in a large cohort study Read more

Global survey sheds light on geographic atrophy’s heavy toll on life quality, calls for broader disease education
Date: Apr 20, 2022
Global survey sheds light on geographic atrophy’s heavy toll on life quality, calls for broader disease education

A global survey conducted by the Harris Poll found that living with geographic atrophy (GA) causes a substantial emotional burden and impact on independence. Read more

Joint effort with the University of Leicester identifies multiple gene impact in rare sight disorder
Date: Apr 18, 2022
Joint effort with the University of Leicester identifies multiple gene impact in rare sight disorder

For the first time, genetic defects influencing the spectrum of vision development and causing problems in developing babies’ eyes have been described by an international team of health researchers. Read more

Phase IV study aims at investigating safety and efficacy of Vabysmo with a focus on underrepresented population
Date: Apr 18, 2022
Phase IV study aims at investigating safety and efficacy of Vabysmo with a focus on underrepresented population

Genentech has launched a new Phase IV, multicenter, open-label, single-arm clinical trial specifically designed to study Vabysmo™ (faricimab-svoa) in underrepresented populations affected by diabetic macular edema. Read more

Ziemer latest femtosecond laser receives FDA clearance
Date: Apr 16, 2022
Ziemer latest femtosecond laser receives FDA clearance

Ziemer Ophthalmic Systems has received FDA clearance for FEMTO Z8 NEO, the successor of Femtosecond Laser LDV Z8, as announced by the company on April 22. Read more